BioSpace Coverage on LexaGene EUA Studies

by LexaGene | Jan 18, 2021 | Biologics Manufacturing

Home » Biologics Manufacturing » BioSpace Coverage on LexaGene EUA Studies

Read BioSpace’s recent coverage of LexaGene’s plans to submit for FDA Emergency Use Authorization, and how the MiQLab™ system is ideally suited to test for COVID-19 variants at point-of-care.

Read the Full Article Here

LexaGene

LexaGene develops fully automated, rapid molecular testing at the point-of-need for accurate pathogen detection in human clinical diagnostics, veterinary diagnostics, food safety, and other markets.

Survey Says Veterinarians Have an Appetite for In-Clinic Diagnostic Technology

This spring LexaGene conducted a market research survey in conjunction with AAHA to assess the opinions of practicing veterinarians on AMR stewardship and the use of antibiotics in the treatment of companion animals.

The Dawn of the Superbugs

The most menacing of all resistant bacteria are the so called “super bugs”- strains of bacteria that are resistant to several different classes of antibiotics or multidrug resistant.

LexaGene offers North Shore Technology Council (NSTC) and Leadership Team at MassBio a tour of our Beverly Facility

Recently, we welcomed members of North Shore Technology Council and MassBio Leadership Teams into our facility at 500 Cummings Center for a full tour of our office space and laboratory spaces.

Subscribe for Updates

Upcoming Events

No events in this category to show at this time.

See All Events

Latest Resources

Application Note: Rapid Detection of Slow-growing Anaerobe Using MiQLab™ System

Biologics Manufacturing

In this study, slow-growing bacterium and typical contaminant, C. acnes, was challenged for microbial detection utilizing both LexaGene’s MiQLab System and anaerobic culture.

1 2 3 4 Next »

See All Resources